Qiagen tops Q2 outlook with flat sales, reaffirms 2026 guidance

Go back to Qiagen tops Q2 outlook with flat sales, reaffirms 2026 guidance

QIAGEN Exceeds Q2 2026 Outlook as Pillars Deliver Solid Sales Growth; Reaffirms Full-Year Outlook

August 5, 2026 4:05 PM EDT

Q2 2026 results: Net sales of $535 million unchanged compared with Q2 2025 on a reported basis and at constant exchange rates (CER), exceeding the outlook for an about 2% CER decline Growth pillars deliver about 5% CER growth, led by Sample technologies, QIAcuity and QDI; QuantiFERON sales rise slightly amid lower U.S. immigration testing demand Adjusted operating income margin of 29.4%, maintaining a high level of profitability Diluted EPS of $0.50; adjusted diluted EPS of $0.62 on a reported and CER basis, above the outlook for at least $0.60... More